Cipla Pharma Pune License Cancelled as FDA Seals Reactin Plus Stock

The Food and Drug Administration (FDA) has cancelled the manufacturing license of Cipla Pharma’s Pune unit after discovering unauthorised promotional text on its packaging. Authorities seized physical stock of the drug Reactin Plus valued at ₹11.19 lakh and issued a strict directive for the firm